

Italian Melanoma Intergroup

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/8076679/publications.pdf>

Version: 2024-02-01

32
papers

1,319
citations

471509

17
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

2499
citing authors

#	ARTICLE	IF	CITATIONS
1	Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center. <i>Vaccines</i> , 2022, 10, 999.	4.4	3
2	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	3.7	20
3	Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone. <i>Cytotherapy</i> , 2018, 20, 851-860.	0.7	3
4	Dabrafenib+trametinib combination in "field-practice": an Italian experience. <i>Future Oncology</i> , 2018, 14, 2045-2052.	2.4	3
5	Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC) Tj ETQq1 1 0.7843 14rgBT /Overlock 10		
6	Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies. <i>Medical Hypotheses</i> , 2018, 119, 26-28.	1.5	3
7	Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. <i>Melanoma Research</i> , 2017, 27, 351-357.	1.2	14
8	Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN- γ in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. <i>Journal of Translational Medicine</i> , 2014, 12, 209.	4.4	26
9	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. <i>Journal of Translational Medicine</i> , 2014, 12, 262.	4.4	21
10	MicroRNAs and dendritic cell-based vaccination in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 181-189.	1.2	9
11	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
12	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. <i>Journal of Translational Medicine</i> , 2013, 11, 135.	4.4	57
13	Ipilimumab in advanced melanoma. <i>Melanoma Research</i> , 2012, 22, 263-270.	1.2	47
14	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	4.2	118
15	Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. <i>International Journal of Oncology</i> , 2011, 39, 1011-7.	3.3	25
16	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	4.4	500
17	Dendritic cell-based vaccine in advanced melanoma. <i>Melanoma Research</i> , 2011, 21, 524-529.	1.2	36
18	Erratum to "Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis". <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-1.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 27-34.	4.2	9
20	Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-9.	3.3	17
21	FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy. <i>Journal of Translational Medicine</i> , 2010, 8, 52.	4.4	5
22	Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). <i>Expert Review of Dermatology</i> , 2009, 4, 199-210.	0.3	11
23	Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. <i>Langenbeck's Archives of Surgery</i> , 2009, 394, 1079-1084.	1.9	10
24	Human embryo immune escape mechanisms rediscovered by the tumor. <i>Immunobiology</i> , 2009, 214, 61-76.	1.9	17
25	Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. <i>Melanoma Research</i> , 2009, 19, 100-105.	1.2	7
26	Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon- α -2b Adjuvant Therapy for Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 675-678.	2.4	7
27	Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. <i>Journal of Translational Medicine</i> , 2006, 4, 36.	4.4	39
28	Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. <i>Journal of Surgical Oncology</i> , 2004, 87, 46-52.	1.7	41
29	Evaluation of in vivo labelled dendritic cell migration in cancer patients. <i>Journal of Translational Medicine</i> , 2004, 2, 27.	4.4	109
30	Dendritic cell vaccination and immunostimulation in advanced melanoma. <i>Expert Review of Vaccines</i> , 2003, 2, 825-833.	4.4	5
31	Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma. <i>Journal of Immunotherapy</i> , 2003, 26, 156-162.	2.4	22
32	Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 185-193.	4.2	21